Literature DB >> 28063386

Attitudes towards and rationale for antipsychotic polypharmacy among psychiatrists in Nigeria: Characteristics associated with high reported antipsychotic polypharmacy.

B O James1, J O Omoaregba2, S O Raji2, O E Imishue3, K M Okonoda4, Y I Nyamali5, P A Famuyiwa6, C U Correll7.   

Abstract

Antipsychotic polypharmacy (APP) is commonplace despite lacking evidence of its effectiveness. We aimed to identify psychiatrists' rationale for and attitudes towards APP and to determine if attitudes influence antipsychotic polypharmacy prescription rates in a survey of a nationally representative sample of Nigerian psychiatrists (of which a majority were senior trainees: 74.2%). Prescriber characteristics, practices and attitudes were compared in 'high' (>30%) vs. 'low' (≤30%) antipsychotic polypharmacy prescribers and results were adjusted for multiple comparisons. Altogether, prescribers reported utilizing antipsychotic polypharmacy in 36.2% of their patients. Compared to 'low' antipsychotic polypharmacy prescribers, 'high' prescribers were significantly more likely using first-generation antipsychotics (FGA) combination, to have attempted a switch to monotherapy in less patients, or been successful in doing so. 'High' and 'low' antipsychotic polypharmacy prescribers were equally moderately concerned about the effects of antipsychotic polypharmacy and also did not differ regarding reasons not justifying antipsychotic polypharmacy. In a multivariable, backward elimination logistic regression model, 'low' antipsychotic polypharmacy was associated with having successfully switched patients to monotherapy, whereas the 'high' antipsychotic polypharmacy was associated with preferring FGA+FGA combinations and aiming for a reduction of non-antipsychotic medications. Antipsychotic polypharmacy is common among psychiatrists in Nigeria, with 'high' and 'low' antipsychotic polypharmacy prescribers sharing similar concerns/attitudes, but differing regarding their primary aim for antipsychotic polypharmacy and in their specific antipsychotic polypharmacy use characteristics.
Copyright © 2017 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Antipsychotic polypharmacy; Nigeria; Psychiatrists; Rationale; Reasons; Survey

Mesh:

Substances:

Year:  2016        PMID: 28063386     DOI: 10.1016/j.psychres.2016.12.032

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  4 in total

1.  Polypharmacotherapy in Psychiatry: Global Insights from a Rapid Online Survey of Psychiatrists.

Authors:  Michal Ordak; Daria Tkacz; Aniela Golub; Tadeusz Nasierowski; Magdalena Bujalska-Zadrozny
Journal:  J Clin Med       Date:  2022-04-11       Impact factor: 4.964

2.  Prescribing Patterns of Psychotropic Drugs and Risk of Violent Behavior: A Prospective, Multicenter Study in Italy.

Authors:  E di Giacomo; A Stefana; V Candini; G Bianconi; L Canal; M Clerici; G Conte; M T Ferla; L Iozzino; G Sbravati; G Tura; R Micciolo; G de Girolamo
Journal:  Int J Neuropsychopharmacol       Date:  2020-05-27       Impact factor: 5.176

3.  Antipsychotic polypharmacy and clozapine prescribing patterns: evolution and correlates before and after a psychiatric hospitalisation.

Authors:  Juliette Lagreula; Philippe de Timary; Laure Elens; Olivia Dalleur
Journal:  Ther Adv Psychopharmacol       Date:  2022-08-23

4.  At-risk individuals display altered brain activity following stress.

Authors:  J M C van Leeuwen; M Vink; G Fernández; E J Hermans; M Joëls; R S Kahn; C H Vinkers
Journal:  Neuropsychopharmacology       Date:  2018-02-26       Impact factor: 7.853

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.